Platelet serotonin reuptake inhibition and response to SSRIs in depressed adolescents

American Journal of Psychiatry

Volumn 162, Issue 4, 2005, Pages 802-804

  Axelson, David A ^a   Perel, James M ^a   Birmaher, Boris ^a   Rudolph, George ^a   Nuss, Sharon ^a   Yurasits, Linda ^a   Bridge, Jeffrey ^a   Brent, David A ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CITALOPRAM; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ARTICLE; CLINICAL ARTICLE; DEPRESSION; FEMALE; HUMAN; MALE; PHARMACODYNAMICS; PRIORITY JOURNAL; RATING SCALE; SEROTONIN UPTAKE; SYMPTOMATOLOGY; THROMBOCYTE; TREATMENT OUTCOME;

ADOLESCENT; AGE FACTORS; BIOLOGICAL MARKERS; BLOOD PLATELETS; CARRIER PROTEINS; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 16844364264     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.162.4.802     Document Type: Article

References (13)

1. Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, Carmody T, Rintelmann J: A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997; 54:1031-1037
2. Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, Ernest DE, Brown EB, Nilsson M, Jacobson JG: Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2002; 41:1205-1215
3. Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, Birmaher B, Hagino OR, Koplewicz H, Carlson GA, Clarke GN, Emslie GJ, Feinberg D, Geller B, Kusumakar V, Papatheodorou G, Sack WH, Sweeney M, Wagner KD, Weller EB, Winters NC, Oakes R, McCafferty JP: Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001; 40:762-772
4. Lesch KP, Wolozin BL, Murphy DL, Reiderer P: Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. J Neurochem 1993; 60:2319-2322
5. 11C]DASB PET imaging study. Am J Psychiatry 2001; 158:1843-1849
6. Preskorn SH: Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997; 32(suppl 1):1-21
7. Axelson DA, Perel JM, Birmaher B, Rudolph GR, Nuss S, Bridge J, Brent DA: Sertraline pharmacokinetics and dynamics in adolescents. J Am Acad Child Adolesc Psychiatry 2002; 41:1037-1044
8. Chambers WJ, Puig-Antich J, Hirsch M, Paez P, Ambrosini PJ, Tabrazi MA, Davies M: The assessment of affective disorders in children and adolescents by semistructured interview: test-retest reliability of the Schedule for Affective Disorders and Schizophrenia for School-Age Children, Present Episode Version. Arch Gen Psychiatry 1985; 42:696-702
9. Beck AT, Ward C, Mendelson M, Mock J, Erbaugh J: An inventory for measuring depression. Arch Gen Psychiatry 1961; 4:561-571
10. Kovacs M: Children's Depression Inventory: Manual. Tonawanda, NY, Multi-Health Systems, 1992
11. Tuomisto J, Tukianen E, Ahlfors UG: Decreased uptake of 5-hydroxytryptamine in blood platelets from patients with endogenous depression. Psychopharmacology (Berl) 1979; 65:141-147
12. Rasmussen BB, Brosen K: Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interaction of the selective serotonin reuptake inhibitors? Ther Drug Monit 2000; 22:143-154
13. US Food and Drug Administration: FDA Issues Public Health Advisory: Reports of Suicidality in Pediatric Patients Being Treated With Antidepressant Medications for Major Depressive Disorder (MDD). FDA Talk Paper T03-70. Washington, DC, FDA, Oct 27, 2003